Putative tumour suppressor gene necdin is hypermethylated and mutated in human cancer
Open Access
- 2 April 2013
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 108 (6) , 1368-1377
Abstract
Background: Necdin (NDN) expression is downregulated in telomerase-immortalised normal human urothelial cells. Telomerase-immortalised normal human urothelial cells have no detected genetic alterations. Accordingly, many of the genes whose expression is altered following immortalisation are those for which epigenetic silencing is reported. Methods: NDN expression was examined in normal tissues and tumour cell lines by quantitative real-time PCR and immunoblotting. Immunohistochemistry was performed on urothelial carcinoma (UC). Urothelial carcinoma and UC cell lines were subject to HumanMethylation27 BeadChip Array-based methylation analyses. Mutation screening was performed. The functional significance of NDN expression was investigated using retroviral-mediated downregulation or overexpression. Results: NDN protein was widely expressed in normal tissues. Loss of expression was observed in 38 out of 44 (86%) of UC cell lines and 19 out of 25 (76%) of non-UC cell lines. Loss of NDN protein was found in the majority of primary UC. Oncomine analysis demonstrated downregulation of expression in multiple tumour types. In UC, tumour-specific hypermethylation of NDN and key CpG sites where hypermethylation correlated with reduced expression were identified. Six novel mutations, including some of predicted functional significance, were identified in colorectal and ovarian cancer cell lines. Functional studies showed that NDN could suppress colony formation at low cell density and affect anchorage-independent growth and anoikis in vitro. Conclusion: NDN is a novel tumour suppressor candidate that is downregulated and hypermethylated or mutated in cancer.Keywords
This publication has 40 references indexed in Scilit:
- Prognostic Biomarkers for Esophageal Adenocarcinoma Identified by Analysis of Tumor TranscriptomePLOS ONE, 2010
- Modeling Oncogenic Signaling in Colon Tumors by Multidirectional Analyses of Microarray Data Directed for Maximization of Analytical ReliabilityPLOS ONE, 2010
- p53 Regulates Hematopoietic Stem Cell QuiescenceCell Stem Cell, 2009
- BMI-1 Promotes Ewing Sarcoma Tumorigenicity Independent ofCDKN2ARepressionCancer Research, 2008
- Genes Involved in Differentiation, Stem Cell Renewal, and Tumorigenesis Are Modulated in Telomerase-Immortalized Human Urothelial CellsMolecular Cancer Research, 2008
- The Diasporin Pathway: a tumor progression-related transcriptional network that predicts breast cancer survivalClinical & Experimental Metastasis, 2008
- Transcriptome Profile of Human Colorectal AdenomasMolecular Cancer Research, 2007
- Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromesOncogene, 2007
- Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancerOncogene, 2007
- Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disordersEuropean Journal of Human Genetics, 2002